NRC Health NRC R2KR3KPHARMA
Company Overview
NRC Health provides analytics and insights to measure and improve patient and employee experience for healthcare organizations in the United States. The company offers market experience solutions, a subscription-based services for improved tracking of awareness, perception, and consistency of healthcare brands; assessment of differentiators; and segmentation tools to evaluate the needs, wants, and behaviors of communities through assessments. It also provides patient experience solutions, a cross-continuum multi-mode digital platform that collects and measures data to improve patient experience, engagement, and loyalty; employee experience solutions, which combines health care with technology comprising engagement, pulse, lifecycle, culture of safety, and magnet RN satisfaction; and consumer experience solution that offers online reputation solutions, community insights, and cross-journey listening through nGage. In addition, the company offers Huey, an AI engine built for Human Understanding that serves as a healthcare experience management companion; and governance solutions provided through national conferences, publications, advisory services, and an online portal for not-for-profit health system boards of directors, executives, and physician leadership. Further, it provides patient experience, service recovery, care transitions, employee engagement, reputation management, rounding, and brand loyalty. The company was formerly known as National Research Corporation and changed its name to NRC Health April 2026. The company was founded in 1981 and is headquartered in Lincoln, Nebraska.
Why Investors Should Care
Generates a return on equity of 42.0%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 23.0%.
Offers a dividend yield of 3.27%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $137.39M (-4.0% YoY); net profit $11.29M.
- Trailing 12 Months Year-on-year growth — revenue +4.0%, earnings -54.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 5.6%, profit CAGR 1.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 5.57% |
| 1 Year: | 4.00% |
Compounded Profit Growth
| 5 Years: | 1.92% |
| 1 Year: | -54.43% |
Stock Price Performance
| 1 Year: | +43.10% |
| 6 Months: | +50.10% |
| 3 Months: | +13.37% |
| 1 Month: | +10.58% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)53.07 · Neutral
P/E of 89.71 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 42.0%.
- Healthy ROCE of 23.0%.
- Attractive dividend yield of 3.27%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 89.7.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NRC NRC Health R2KR3KPHARMA | 21.53 | 89.71 | $476.66M | 3.27% | 22.99% | 42.03% | 5.57% | 1.92% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 31.48M | 31.41M | 32.47M | 33.86M | 31.17M | 33.48M | 35.46M | 36.42M | 37.77M | 38.44M | 37.29M | 37.69M | 36.47M | 36.16M | 37.95M | 35.31M | 35.02M | 35.82M | 33.55M | 34.04M | 34.61M | 34.80M | 35.39M |
| Operating Income | 5.53M | 6.03M | 8.40M | 6.32M | 7.16M | 5.83M | 6.36M | 6.55M | 8.01M | 7.02M | 7.34M | 9.98M | 8.45M | 7.12M | 8.96M | 7.76M | 9.17M | 10.70M | 10.15M | 10.22M | 11.19M | 9.28M | 12.02M | 12.02M | 12.24M | 13.14M | 11.70M | 11.50M | 11.11M | 9.02M | 9.37M | 9.96M | 8.76M | 8.87M | 7.98M | 8.60M | 1.59M | 7.74M | 5.57M | -3.24M |
| Net Income | 3.43M | 3.81M | 5.45M | 4.05M | 4.55M | 3.48M | 4.06M | 4.14M | 5.51M | 4.56M | 4.73M | 6.52M | 5.75M | 4.15M | 7.31M | 7.95M | 6.99M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.28M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.32 | 0.29 | 0.31 | 0.46 | 0.30 | 0.37 | 0.36 | 0.35 | 0.38 | 0.34 | 0.33 | 0.33 | 0.28 | 0.29 | 0.32 | 0.27 | 0.26 | 0.24 | 0.25 | -0.01 | 0.18 | 0.14 | -0.15 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 57.69M | 63.40M | 75.77M | 86.42M | 92.59M | 98.84M | 102.34M | 109.38M | 117.56M | 119.69M | 127.98M | 133.28M | 147.95M | 151.57M | 148.58M | 143.06M | 137.39M |
| Operating Income | 13.70M | 13.86M | 18.73M | 22.72M | 24.81M | 28.30M | 26.45M | 31.20M | 34.22M | 35.27M | 43.03M | 42.68M | 50.27M | 46.54M | 40.05M | 35.19M | 22.59M |
| Net Income | 8.49M | 11.56M | 11.56M | 15.07M | 15.48M | 18.16M | 17.61M | 20.52M | 22.94M | 30.05M | - | 37.20M | 37.45M | 31.78M | 30.96M | 24.78M | 11.29M |
| Diluted EPS | 1.26 | 1.26 | 1.69 | 2.17 | - | - | - | - | - | - | 1.26 | 1.45 | 1.46 | 1.27 | 1.25 | 1.04 | 50.00 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 95.77M | 100.68M | 100.05M | 111.09M | 129.51M | 128.05M | 120.62M | 127.32M | 108.03M | 110.69M | 133.42M | 157.54M | 130.46M | 122.44M | 132.54M | 134.88M |
| Total Equity | 38.60M | 44.17M | 48.58M | 55.55M | 56.74M | 71.75M | 87.75M | 74.22M | 82.81M | 90.04M | 19.08M | 32.89M | 64.31M | 85.34M | 72.03M | 48.95M | 31.28M | 13.99M |
| Cash & Equivalents | 1.11M | 2.51M | 3.52M | 8.08M | 8.29M | 22.09M | 40.04M | 42.15M | 33.02M | 34.73M | 12.99M | 13.52M | 34.69M | 54.36M | 25.03M | 6.65M | 4.23M | 4.14M |
| Long Term Debt | - | - | - | 14.49M | 12.44M | 8.07M | 5.74M | 3.34M | 857.00K | 1.07M | 34.18M | 29.80M | 26.55M | 26.62M | 22.32M | 29.47M | 57.90M | 75.02M |
| Total Liabilities | - | - | 47.19M | 45.12M | 43.30M | 39.33M | 41.76M | 53.83M | 37.82M | 37.27M | 88.95M | 77.79M | 69.11M | 72.20M | 58.43M | 73.48M | 101.25M | 120.89M |
| Current Liabilities | - | - | 26.15M | 24.40M | 35.30M | 23.78M | 27.93M | 44.17M | 31.51M | 32.31M | 47.11M | 38.16M | 31.68M | 40.39M | 33.42M | 36.20M | 35.86M | 36.62M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 13.67M | 14.60M | 18.48M | 19.13M | 19.32M | 26.20M | 21.89M | 26.84M | 28.09M | 39.85M | 40.92M | 40.64M | 46.34M | 36.27M | 38.11M | 34.62M | 26.45M |
| Investing Cash Flow | -3.00M | -16.98M | -6.93M | -2.35M | -2.19M | -5.72M | -1.33M | -3.75M | -6.12M | -5.97M | -4.66M | -3.72M | -8.51M | -9.84M | -15.78M | -20.28M | -10.71M |
| Financing Cash Flow | -9.55M | 3.25M | -6.89M | -16.69M | -2.82M | -1.73M | -16.87M | -32.50M | -21.12M | -54.50M | -36.35M | -15.50M | -18.16M | -55.58M | -40.71M | -16.76M | -15.84M |
| Capital Expenditure | -2.91M | -1.54M | -2.81M | -2.35M | -2.19M | -2.49M | -2.94M | -3.97M | -4.57M | -5.97M | -4.66M | -3.98M | -5.51M | -9.84M | -15.78M | -15.45M | -10.71M |
| Free Cash Flow | 10.76M | 13.06M | 15.67M | 16.78M | 17.13M | 23.70M | 18.95M | 22.87M | 23.52M | 33.88M | 36.26M | 36.65M | 40.83M | 26.43M | 22.33M | 19.18M | 15.74M |
| Share Buybacks | 84.00K | 399.00K | - | - | - | - | 1.67M | - | - | - | - | - | 4.14M | 27.62M | 19.10M | 30.95M | 20.18M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 23.7% | 21.9% | 24.7% | 26.3% | 26.8% | 28.6% | 25.8% | 28.5% | 29.1% | 29.5% | 33.6% | 32.0% | 34.0% | 30.7% | 27.0% | 24.6% | 16.4% |
| Net Margin % | 14.7% | 18.2% | 15.3% | 17.4% | 16.7% | 18.4% | 17.2% | 18.8% | 19.5% | 25.1% | - | 27.9% | 25.3% | 21.0% | 20.8% | 17.3% | 8.2% |
| ROE % | 19.2% | 23.8% | 20.8% | 26.6% | 21.6% | 20.7% | 23.7% | 24.8% | 25.5% | 157.5% | - | 57.8% | 43.9% | 44.1% | 63.2% | 79.2% | 80.7% |
| ROCE % | - | 19.9% | 24.6% | 35.1% | 28.4% | 27.9% | 31.5% | 35.0% | 36.0% | 57.9% | 59.3% | 41.9% | 42.9% | 48.0% | 46.4% | 36.4% | 23.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Kayne Anderson Rudnick Investment Management LLC | 9.01% | 2.03M | $44.37M |
| 2 | Blackrock Inc. | 4.71% | 1.06M | $23.19M |
| 3 | Morgan Stanley | 3.81% | 859.27K | $18.78M |
| 4 | Vanguard Capital Management LLC | 2.96% | 666.55K | $14.56M |
| 5 | Dimensional Fund Advisors LP | 2.18% | 491.23K | $10.73M |
| 6 | Willis Investment Counsel | 1.93% | 434.79K | $9.50M |
| 7 | Geode Capital Management, LLC | 1.86% | 420.06K | $9.18M |
| 8 | QV Investors Inc. | 1.65% | 372.50K | $8.14M |
| 9 | Farmers & Merchants Investments Inc | 1.47% | 330.65K | $7.22M |
| 10 | Renaissance Technologies, LLC | 1.44% | 325.38K | $7.11M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NRC
A healthcare executive calls a rounding tool a “strategic partner.” It scores 91.6 in a KLAS report. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPaWF0cHNMN1JzdjBla2NMOFJnOXk4bnZFVlN1T21kdFZUdy1lY1FpMEtGY1BQZWVmamdJbk1qOFN2LS1BaDJvVkozUURvUXlrMERzMDFmQTNSajI2X2JZUU5XcTVBSTVJSVNVNHFTLXV2MF96RV84V19QSTRnWFY1SjNaOVFmNW40aFRpY0…
(NRC) Risk Channels and Responsive Allocation - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNZk5NeElyWkxQOUxMNzRCcGdrR2RHQ0E5TjkyLXh4ZHh0MEREaGo3R3dVSy1zLVktaUpwbFFtMHhhaDg0bXplRFlxM1dBU3ZYUzRIT3A4Z0xNYi04Rnd4d2c1ZTRlSVIydi1QZnJYWlhJWElQLXh3RWVyWXp6Z2dfMExiSTZEMjd4N0NBS2…
NRC Group (OB:NRC) Stock Profit Recovery Meets A Rich P E Reality - webull.com
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE1ILWxMdDVucXk3b05hYjB1dU5VSTRPT01Bd2tOUllwWEd6eTM1Mm1vNlJ2N1pDV3IzWE1odmo0YXhVVlZERFNXd1g3U01GNjA1V0FaN2M5Y00?oc=5" target="_blank">NRC Group (OB:NRC) Stock Profit Recovery Meets A…
Two new awards join NRC Health honors for hospitals and medical groups - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxOSHFEdjd6Q3JDT2k0dGthcHdmTE1jS3ZQX1RsUjdSWDFUNk1UdjBrTTRWNFlqbFZGZm15dUdXdjA3TEM1dXpKTVNENzRoRDN5VEJPNV96bFV2ODZjZjZVU3ZBVVpOalQzZ2NaUDR1TEdxTjQ1cDZvV3lRUkxBeVNDRVc1LXV5RkxPM0hMUD…
NRC Health (NRC) Stock Sinks As Margin Compression Deepens Earnings Pain - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxQeFgyYUdiNE5ZRGFWNjJHZWczNnNsaHpfM3dHbHhwdzZxYUpmUGhOZW43NndpOG1IOTVXa2VGbHRvcmZkaXg2bDVJeGQxdmZCM3pqMXRLbDNJY3hzdTZqaWlvcDR0YTJiWUgwUHltUUR4MFIxWWIxLXZFWTJmZEdHTE05eldqNVZHbGFJRm…
A Look at NRC Health (NRC) After 4.3% Decline -- GF Value $19.97 vs Price $20.94 - GuruFocus
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPaTB2XzBfOTJENWNlN0tKR2huNW5oa2pNR3JzeWxZODlfSUw0NFEzeWdKNEFhazdXY0VsZnNJQ2cwdEJUbm1xc1lVWEp5cVlyZXlMNTVoNUJER09POXFoNXVUWFg5R3dPRHVlTkxKV21UYkxxai1QT1VVZGxhTURFWEM3VGV1bS1uaG5wOE…
NRC — Frequently Asked Questions
What is the current share price of NRC Health (NRC)?
As of 2026-09-07 16:24 PDT, NRC Health (NRC) trades at $21.53 on NasdaqGS. Its 52-week range is $11.13 to $22.77.
What is the market capitalisation of NRC?
NRC Health (NRC) has a market capitalisation of $476.66M on NasdaqGS.
What is the P/E ratio of NRC?
NRC trades at a trailing price-to-earnings (P/E) ratio of 89.71. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 68.72.
Does NRC pay a dividend?
NRC Health (NRC) currently offers a dividend yield of 3.27%.
What is the return on equity (ROE) of NRC?
NRC has a return on equity (ROE) of 42.03%. Its return on capital employed (ROCE) is 22.99%.
Is NRC a good stock to buy?
This page provides a data-driven analysis of NRC Health (NRC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.